What is Immage Biotherapeutics Corp?
does not have significant business operations.
IMMG · Verdict
Moderate reward · elevated risk
IMMG's standout is balance sheet; cash flow and volatility weigh on the picture.
Based on 88% data coverage
IMMG · Verdict
Current ratio 3.67
Weak vs peers
Weak vs peers
-1134% return on equity
Earnings +162.2% CAGR
Model-based scoring. For information only — not financial advice.
does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 15.17K.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.